R-tru-tide 10mg

A triple-agonist targeting GLP-1, GIP, and glucagon receptors, is gaining attention for its unprecedented weight-loss results and metabolic benefits in early trials. With up to 24 percent average body weight reduction in high-dose groups at 48 weeks, this drug could reshape obesity and metabolic disease treatment.